Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord blood + cytarabine
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Dalian Medical University
- Modality
- Stem Cell Therapies → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
Umbilical cord blood + cytarabine is a combination therapeutic regimen involving the infusion of third-party umbilical cord blood (UCB) following cytarabine-based chemotherapy. Developed by the Hematology Department at The First Affiliated Hospital of Dalian Medical University, this approach is primarily investigated for the treatment of acute myeloid leukemia (AML), particularly in patients who are not candidates for standard allogeneic hematopoietic stem cell transplantation. Cytarabine, a pyrimidine analogue, acts as an antimetabolite that inhibits DNA polymerase and incorporates into DNA, leading to the death of rapidly dividing leukemic cells. The subsequent infusion of third-party UCB provides hematopoietic stem and progenitor cells intended to accelerate hematopoietic recovery and potentially induce a graft-versus-leukemia (GVL) effect, where the donor immune cells help eliminate residual malignant cells without the need for full donor-host matching or intensive conditioning.
- Other names
- Third-party umbilical cord blood infusion plus cytarabineUCBI plus chemotherapyThird-party umbilical cord blood infusion combined with chemotherapy
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on umbilical cord blood + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord blood + cytarabine.